Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection

1997 ◽  
Vol 61 (1) ◽  
pp. 30-32 ◽  
Author(s):  
N. I. J. Paton ◽  
D. C. Macallan ◽  
G. E. Griffin ◽  
M. Pazianas
Keyword(s):  
Bone Mineral Density ◽  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Bone Mineral ◽  
Mineral Density ◽  
Immunodeficiency Virus

scholarly journals Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age

2020 ◽  
Author(s):  
Jane C Lindsey ◽  
Denise L Jacobson ◽  
Hans M Spiegel ◽  
Catherine M Gordon ◽  
Rohan Hazra ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Bone Mineral ◽  
Mineral Density ◽  
Safety And Efficacy ◽  
Low Bone Mineral Density ◽  
Perinatal Hiv ◽  
Immunodeficiency Virus ◽  
Randomized Crossover Study

Abstract No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.

scholarly journals Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected Individuals

2003 ◽  
Vol 36 (4) ◽  
pp. 482-490 ◽  
Author(s):  
Kristin Mondy ◽  
Kevin Yarasheski ◽  
William G. Powderly ◽  
Michael Whyte ◽  
Sherry Claxton ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Human Immunodeficiency Virus ◽  
Bone Mineral ◽  
Bone Markers ◽  
Mineral Density ◽  
Immunodeficiency Virus

scholarly journals Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age

2019 ◽  
Vol 71 (5) ◽  
pp. 1281-1288 ◽  
Author(s):  
Denise L Jacobson ◽  
Jane C Lindsey ◽  
Catherine Gordon ◽  
Rohan Hazra ◽  
Hans Spiegel ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Human Immunodeficiency Virus ◽  
Children And Adolescents ◽  
Bone Mineral ◽  
Whole Body ◽  
Mineral Density ◽  
Safety And Efficacy ◽  
Immunodeficiency Virus ◽  
Perinatally Infected

Abstract Background Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youths living with HIV. Methods Fifty-two children and adolescents (aged 11–24 years) perinatally infected with HIV with low lumbar spine (LS) BMD (Z score < −1.5) were randomized to receive once-weekly alendronate or placebo in a double-blind cross-over study designed to assess the safety and efficacy of 48 and 96 weeks of alendronate in the United States and Brazil. All participants received daily calcium carbonate and vitamin D supplementation and were asked to engage in regular weight-bearing exercise. Safety and efficacy are summarized for the initial 48 weeks of the trial. Results Grade 3 or higher abnormal laboratory values, signs, or symptoms developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (P > .99). No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were reported. Mean increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendronate (20% [14%–25%]) than placebo (7% [5%–9%]) (P < .001). Similar improvements were seen for whole body BMD. Conclusions In this small study in children and adolescents perinatally infected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone. Clinical Trials Registration NCT00921557.

Sign in / Sign up

Export Citation Format

Share Document